Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Biwei Cao

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Frontiers in Immunology|March 13, 2020
Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving ImmunotherapySaurabh K Garg, Matthew J Ott, A G M Mostofa, et al.
International Journal of Radiation Oncology, Biology, Physics|July 9, 2021
Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell TherapyNicholas B Figura, Timothy J Robinson, Austin J Sim, et al.
Bone Marrow Transplantation|July 5, 2025
Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamideJena Schmitz, Eric Gaskill, Samantha Price, et al.
Journal for Immunotherapy of Cancer|November 30, 2022
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanomaNikhil I Khushalani, Melinda Vassallo, Judith D Goldberg, et al.
Transplantation and Cellular Therapy|May 13, 2024
Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell LymphomaYumeng Zhang, Ashley Rose, Sushmita Khadka, et al.
Haematologica|April 25, 2020
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphomaJennifer M Logue, Elisa Zucchetti, Christina A Bachmeier, et al.
Blood|January 29, 2021
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphomaMichael D Jain, Hua Zhao, Xuefeng Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene CiloleucelRawan Faramand, Michael Jain, Verena Staedtke, et al.
Blood|July 24, 2024
JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial resultsJoseph Pidala, Shernan G Holtan, Kelly Walton, et al.
Blood Cancer Discovery|January 9, 2024
Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell LymphomaRawan G Faramand, Sae Bom Lee, Michael D Jain, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Frontiers in Immunology|March 13, 2020
Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving ImmunotherapySaurabh K Garg, Matthew J Ott, A G M Mostofa, et al.
International Journal of Radiation Oncology, Biology, Physics|July 9, 2021
Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell TherapyNicholas B Figura, Timothy J Robinson, Austin J Sim, et al.
Bone Marrow Transplantation|July 5, 2025
Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamideJena Schmitz, Eric Gaskill, Samantha Price, et al.
Journal for Immunotherapy of Cancer|November 30, 2022
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanomaNikhil I Khushalani, Melinda Vassallo, Judith D Goldberg, et al.
Transplantation and Cellular Therapy|May 13, 2024
Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell LymphomaYumeng Zhang, Ashley Rose, Sushmita Khadka, et al.
Haematologica|April 25, 2020
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphomaJennifer M Logue, Elisa Zucchetti, Christina A Bachmeier, et al.
Blood|January 29, 2021
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphomaMichael D Jain, Hua Zhao, Xuefeng Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene CiloleucelRawan Faramand, Michael Jain, Verena Staedtke, et al.
Blood|July 24, 2024
JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial resultsJoseph Pidala, Shernan G Holtan, Kelly Walton, et al.
Blood Cancer Discovery|January 9, 2024
Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell LymphomaRawan G Faramand, Sae Bom Lee, Michael D Jain, et al.
Pageof 6